Wells Fargo Is Well-Positioned for the Upcoming Year; We're Increasing FVE to $65
We are increasing our fair value estimate for Wells Fargo to $65 per share from $60 per share after incorporating the latest results. This fair value estimate is equivalent to 1.6 times the reported ...
Yahoo Finance5d
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
WASHINGTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals ... said 60 Degrees Pharmaceuticals, Inc. Chief Executive Officer, Geoff Dow, PhD. “The chronic phase of babesiosis ...
manilatimes5d
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
"As babesiosis continues to emerge in new regions of the U.S., the need to address its impact safely and effectively is also growing,” said 60 Degrees Pharmaceuticals, Inc. Chief Executive Officer, ...
Nasdaq5d
60 Degrees Pharmaceuticals, Inc. Receives IRB Approval for Phase II Clinical Study of Tafenoquine in Chronic Babesiosis Treatment
60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine ...
Yahoo Finance4d
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial
US-based pharmaceutical company 60 Degrees Pharmaceuticals has received approval from the investigational review board (IRB) for a Phase II trial of Arakoda (tafenoquine) for treating chronic ...
Nasdaq5d
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is ...